Posted by Michael Wonder on 27 Sep 2023
Mythic Therapeutics receives FDA fast track designation for MYTX-011 for patients with non-small cell lung cancer with cMET over-expression
26 September 2023 - This designation encompasses non-small-cell lung cancer patients with any level of cMET over-expression, including low and intermediate, and potentially accelerates the path to regulatory filing in the US.
Mythic Therapeutics today announced that the US FDA has granted fast track designation to Mythic’s investigational cMET-targeting antibody-drug conjugate, MYTX-011, for the treatment of patients with non-small-cell lung cancer with cMET over-expression.
